Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes Journal Article


Authors: Faltas, B. M.; Gennarelli, R. L.; Elkin, E.; Nguyen, D. P.; Hu, J.; Tagawa, S. T.
Article Title: Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes
Abstract: Background Metastatic urothelial carcinoma of the bladder, ureter, or renal pelvis is a highly aggressive disease with poor outcomes. Even with platinum-based chemotherapy, the median overall survival is 15 months and the 5-year survival is only 15%. The role of metastasectomy in urothelial carcinoma is currently undefined. Objective To examine the use and outcomes of metastasectomy in older patients with urothelial carcinoma in a large population-based dataset. Design, setting, and participants We conducted a SEER-Medicare study, and from 70,648 urothelial carcinoma patients who met inclusion criteria, we identified 497 patients who had at least 1 metastasectomy during a median follow-up of 40 months. Outcome measurements and statistical analysis The primary study endpoints were metastasectomy use, the length of stay for metastasectomy, complications, and overall survival following metastasectomy. Secondary outcomes included 30-day mortality and readmission rate following metastasectomy. Results and limitations We identified 497 patients meeting inclusion criteria who had at least 1 metastasectomy during the study period including 24 patients who had more than 1 procedure resulting in a total of 523 metastasectomies. The median overall survival after the first metastasectomy was 19 months (95% CI: 15–23; interquartile range: 4–74). In this selected patient population, over a third of patients were alive at 3 years. In the 476 patients who had evaluable discharge dates, the median length of stay after metastasectomy was 7 days (IQR: 4–12), and 10% of patients had at least 1 complication within 30 days of discharge. Thirty-day mortality after metastasectomy was 10% (n = 53/523) and was largely driven by the mortality associated with resections of urothelial cancer brain metastases. Conclusions In well-selected patients with urothelial carcinoma with a reasonable life expectancy, resection of metastatic lesions is safe and is associated with long-term survival and potential cures. © 2018 Elsevier Inc.
Keywords: cancer chemotherapy; cancer survival; treatment outcome; aged; major clinical study; overall survival; cisplatin; bone metastasis; gemcitabine; paclitaxel; follow up; lymph node metastasis; lymph node dissection; carboplatin; metastasis; lung disease; deep vein thrombosis; bladder cancer; cancer mortality; docetaxel; pneumonia; postoperative complication; medicare; acute kidney failure; length of stay; liver metastasis; lung metastasis; heart infarction; population; surgical infection; brain metastasis; surgery; surgical mortality; hospital discharge; hospital readmission; postoperative hemorrhage; hematoma; transitional cell carcinoma; gastrointestinal disease; life expectancy; urothelial cancer; metastasectomy; metastasis resection; seer-medicare; long term survival; very elderly; human; male; female; priority journal; article
Journal Title: Urologic Oncology: Seminars and Original Investigations
Volume: 36
Issue: 1
ISSN: 1078-1439
Publisher: Elsevier Inc.  
Date Published: 2018-01-01
Start Page: 9.e11
End Page: 9.e17
Language: English
DOI: 10.1016/j.urolonc.2017.09.009
PROVIDER: scopus
PUBMED: 28988653
PMCID: PMC5793883
DOI/URL:
Notes: Article -- Export Date: 2 January 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Elena B Elkin
    163 Elkin